Significant Transactions (Details Textual) |
1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
May 23, 2022 |
Oct. 02, 2021
USD ($)
shares
|
Apr. 02, 2021
USD ($)
shares
|
May 31, 2022
USD ($)
Employees
|
Sep. 30, 2022
USD ($)
$ / shares
shares
|
Sep. 30, 2021
USD ($)
|
Sep. 30, 2022
USD ($)
$ / shares
shares
|
Sep. 30, 2021
USD ($)
|
Dec. 31, 2021
USD ($)
$ / shares
shares
|
Oct. 10, 2022
shares
|
Jul. 05, 2022
shares
|
|
| Business Acquisition [Line Items] | |||||||||||
| Exchangeable shares | shares | 18,094 | 18,094 | |||||||||
| Revenues | $ 5,412,802 | $ 5,135,502 | $ 18,449,524 | $ 14,056,414 | |||||||
| Common stock, shares issued (in shares) | shares | 4,023,294 | 4,023,294 | 1,550,094 | ||||||||
| Preferred stock, par value (in dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 | $ 0.0001 | ||||||||
| Preferred stock, liquidation preference (in dollars per share) | $ / shares | $ 1 | $ 1 | |||||||||
| Transaction costs | $ 600,000 | ||||||||||
| Sales and marketing costs | 300,000 | ||||||||||
| Product development costs | $ 300,000 | ||||||||||
| Aggregate value of exchangeable shares | $ 138,419 | $ 138,419 | |||||||||
| Convertible into shares of common stock per share | $ / shares | $ 3.518 | $ 3.518 | |||||||||
| Number of employees | Employees | 59 | ||||||||||
| Restructuring reduction employees percentage | 33.00% | ||||||||||
| General and administrative expenses | $ 100,000 | ||||||||||
| Fair value of the contingent consideration | $ 6,300,000 | $ 6,300,000 | |||||||||
| Acquisition of net income | $ 1,982,553 | 15,472,157,000 | |||||||||
| Reduction of purchase price | $ 25 | ||||||||||
| Underwriting Agreement, Description | (i) an increase to Common Stock of $217 representing the issuance of 1,469,143 shares of Common Stock attributable to the Units and the issuance of 704,770 shares of Common Stock from the exercise of the Pre-funded Warrants<span>, both at their par value of $0.0001 per share </span>and (ii) an increase to Additional Paid-In Capital of $9.2 million for the amounts received over par value less the underwriting discounts and commissions and related expenses <span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">including legal and other professional fees</span>. | ||||||||||
| Reduction of working capital | $ 1,500,000 | ||||||||||
| Common stock offering percentage | 25.00% | ||||||||||
| Offering shares of common stock | shares | 402,345 | 402,345 | |||||||||
| Initially measured at a fair value | $ 6.3 | ||||||||||
| Underwriter Warrants [Member] | |||||||||||
| Business Acquisition [Line Items] | |||||||||||
| Exchangeable shares | shares | 108,696 | 108,696 | |||||||||
| Underwriter Warrants [Member] | Minimum [Member] | |||||||||||
| Business Acquisition [Line Items] | |||||||||||
| Underwriter warrants to purchase | shares | 108,696 | ||||||||||
| Subsequent Event [Member] | |||||||||||
| Business Acquisition [Line Items] | |||||||||||
| Exchangeable shares issued | shares | 402,345 | ||||||||||
| Warrant [Member] | |||||||||||
| Business Acquisition [Line Items] | |||||||||||
| Underwriting Agreement, Description | Underwriting Agreement and upon closing of the Unit Offering, we issued to the Underwriter warrants to purchase up to 2,173,913 shares of Common Stock (the “Underwriter Warrants” and, together with the Common Warrants and the Pre-Funded Warrants, the “Warrants”), which is 5.0% of the aggregate number of Shares and Shares issuable upon exercise of the Pre-Funded Warrants sold in the Unit Offering. The Underwriter Warrants are exercisable at any time and from time to time, in whole or in part, commencing from six months after June 29, 2022 (the "Effective Date") and ending five years from the Effective Date, at a price per share equal to $0.23, which is the public offering price per unit. | ||||||||||
| Viridian Sciences [Member] | |||||||||||
| Business Acquisition [Line Items] | |||||||||||
| Exchangeable shares | shares | 50,000,000,000 | ||||||||||
| Reduction of contingent consideration | $ 6,000,000 | ||||||||||
| Stock Consideration in Cash | $ 1,000,000 | ||||||||||
| Cannabis [Member] | |||||||||||
| Business Acquisition [Line Items] | |||||||||||
| Cash | 5,000,000 | ||||||||||
| Aggregate stock price | 8 | ||||||||||
| Fair value of the contingent consideration | $ 3.3 | $ 3.3 | |||||||||
| Common stock issued in business combinations | $ 12,000,000 | ||||||||||
| 365 Cannabis [Member] | |||||||||||
| Business Acquisition [Line Items] | |||||||||||
| Cash | 527,000 | 527,000 | |||||||||
| Common stock, shares issued (in shares) | shares | 180,000,000,000 | ||||||||||
| Value of shares issued for exchangeable shares | 11,060,000 | ||||||||||
| Reduction of purchase price | 1,500,000 | ||||||||||
| Receivables booked in other current assets | $ 400,000 | 400,000 | |||||||||
| Reduction of working capital | $ 200,000 | ||||||||||
| Shares held in escrow, value | $ 900,000 | ||||||||||
| Shares held in escrow | shares | 13,988 | ||||||||||